Novel method for decellularizing extracellular matrix
The use of ECM in mammalian subjects was successfully isolated by using surfactant, protease and nuclease treatment from samples of juvenile or juvenile abortion animals with surfactant, protease and nuclease, and the use of ECM in mammalian subjects was solved The immune response problem in the process has achieved efficient decellularization and functional retention of ECM.
Patent Information
- Application Number
- CN202380029468.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-11
- Filing Date
- 2023-02-10
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively obtain an acellular amphibian extracellular matrix (ECM) for mammalian subjects, and its natural cells and genetic material trigger an undesirable immune response.
A novel method is used to remove cells and isolate ECM from juvenile and persistent biological samples of caudal or juvenile aboropsis to ensure the integrity of their structural and functionalities. Store by micronization and dehydration to reduce immunogenicity.
More than 70% of the cells were successfully removed, the residual DNA amount was less than 10 ng/mg, and the length of the DNA fragment was less than 300 bp, reducing the immunogenicity of ECM and making it useful for tissue regeneration and skin conditions in mammals.
Smart Images

Figure CN118973593A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 267,863, filed on February 11, 2022, which is incorporated herein by reference in its entirety. Technical Field
[0002] The present disclosure describes a novel method for decellularizing extracellular matrix and compositions comprising the decellularized extracellular matrix for various uses. Background Art
[0003] Skin is the largest organ of the mammalian body and is the outer covering of the body. It has three major functions: protection from microorganisms and excessive water loss, regulating body temperature, and sensing touch, heat and cold. Mammalian skin has two main layers, the epidermis and the dermis. The epidermis is the outermost layer of the skin, which prevents the entry of microorganisms and keeps the water in our body. It is a stratified squamous epithelium composed of keratinocytes. The dermis is the skin layer below the epidermis, which is where the skin appendages are located and provides elasticity to the skin through an extracellular matrix composed of collagen fibers, elastic fibers, hyaluronic acid and proteoglycans. The dermis and epidermis are separated by a thin fibrous layer called the basement membrane, which regulates the flow of cells and molecules (such as cytokines and growth factors) between the dermis and the epidermis during remodeling, repair and regeneration. Below the dermis is the subcutaneous tissue, which is composed of loose connective tissue (such as fat) and elastin. The main cells of the subcutaneous tissue include fibroblasts, macrophages and adipocytes.
[0004] Injury or disease can cause disruptions in the morphology and function of an organ or tissue (e.g., skin). Remodeling and repair of an organ or tissue after injury is a complex wound healing process involving interactions between cells, growth factors, and the extracellular matrix (ECM). This process in adult mammals involves well-known stages: homeostasis, inflammation, proliferation, maturation, and remodeling. During homeostasis, coagulation occurs to stop bleeding. Inflammation involves the recruitment of leukocytes, antibodies, nutrients, and enzymes to the affected area to accelerate wound healing. During proliferation, new healthy granulation tissue (e.g., new connective tissue and blood vessels) replaces the wound. Maturation and remodeling occur after wound closure and involve repairing dermal tissue to increase its tensile strength.
[0005] In contrast to repair processes, in which the goal is to re-establish function without regard to the exact location of the injured tissue, regeneration is the replacement of injured tissue with an exact replica, resulting in full restoration of morphology and function. For example, uninjured skin will continually undergo full regeneration as new cells are replaced. However, injured adult mammalian skin does not fully regenerate, but instead leaves scars.
[0006] Unlike mammals, urodele species regenerate their skin structures, including the dermis and secretory glands, after deep skin injury without scar formation. It has been reported that the extracellular matrix (ECM) of urodele species may have desirable properties important for wound healing, making it an ideal source of biomaterials for wound healing, xenotransplantation, and other skin conditions. Therefore, urodele species ECM may provide a model for mammalian tissue repair and regeneration and a starting material for compositions for treating mammalian tissues, including skin.
[0007] The ECM of anurans contains native cells and genetic material that are used to maintain structural and biochemical functions and properties. However, the native cells and genetic material of the anuran ECM can induce undesirable effects and immune responses in subjects. Decellularization is a process that removes native cells and genetic material from a tissue without affecting the structural and functional integrity of the tissue. The decellularized tissue can then be used in a subject. However, there is a need to develop an improved method to obtain a decellularized anuran ECM that can be effectively used in a subject, especially a mammalian subject. Summary of the invention
[0008] This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
[0009] The present disclosure provides new and improved methods for decellularizing amphibian biological samples. In embodiments, the biological sample comprises ECM and is harvested from a neotenic Caudata (e.g., Ambystoma hybrids) or a juvenile Apoda (frog / tadpole) species at the larval stage.
[0010] The method comprises washing the sample with one or more surfactants, and incubating the sample with one or more proteases and one or more nucleases. In embodiments, the method comprises washing the sample with one or more detergent solutions, treating the sample with one or more proteases, and treating the protease-treated sample with one or more nucleases to obtain an isolated ECM that can be used in vitro and / or in vivo. The one or more detergent solutions contain one or more nonionic surfactants, such as Triton TM X-100 Reduced, and / or anionic detergents, such as N-lauroylsarcosine (NLS). The one or more proteases include amino endopeptidases, such as dispase II. The one or more nucleases include DNA / RNA endonucleases, such as Nucleases. After decellularization, isolated ECM samples can be micronized and dehydrated for storage.
[0011] The present disclosure also describes isolated ECM and compositions comprising isolated ECM. The isolated ECM has more than 70% of its cells removed, but the structural and / or functional architecture of the ECM remains intact. The isolated ECM contains less than 20 ng / mg of dry ECM (or less than 10 ng / μl of DNA extract). The length of the residual DNA fragments in the isolated ECM is less than 300 base pairs (bp).
[0012] Isolated ECM and compositions can be used in organ and tissue regeneration, as implants, and for treating skin disorders. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1A , 1B , 1C, 1D, 1E, and 1F show slides of isolated ECM stained with hematoxylin and eosin and imaged by light microscopy. Figures 1A-1D A and 1B show samples washed with TritonX-100. Figure 1E and 1F Samples washed with NLS are shown.
[0014] Figure 2A and 2B The amount of DNA in the isolated ECM is shown. Figure 2A The average DNA quantification for each sample is shown. Figure 2B Shown by Figure 2A The concentrations shown are converted to percentage DNA.
[0015] Figure 3A and 3B A 1% agarose gel with a DNA ladder is shown. Figure 3A Residual DNA from original tissue (Nave tissue) and isolated ECM samples (Triton X-100 (T1 or T2) or NLS samples (NLS) from the lower left corner (BLC) or center (C) of isolated ECM samples: T1_BLC, T-_C, T2_BLC, T2_C, NLS_BLC, and NLS_C. Figure 3B Residual DNA from isolated ECM samples was shown in triplicate (3X, three lanes).
[0016] Figure 4A and 4B The average particle length and error bars for the cryo-ground samples are shown. The average lengths of T1 and NLS were 28.36 μm ± 13.19 and 30.05 μm ± 34.70, respectively. The average area of T1 and NLS was 494.06 μm 2 ±293.2 and 631.5 μm2 ±550.91. DETAILED DESCRIPTION
[0017] The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
[0018] The term "antigen" refers to a molecule that is a toxin or foreign to a subject and induces an immune response in the form of antibodies produced against the molecule. The isolated ECM described herein may have reduced antigenicity compared to native ECM, making it useful in a subject.
[0019] The term "biological activity" refers to a biological effect. A substance is biologically active or has biological activity including a substance that has a biological function.
[0020] The term "biocompatible" means that the product and its normal degradation products in vitro, ex vivo or in vivo are useful, practical and / or substantially non-toxic and non-carcinogenic to cells, tissues, organs, organisms or subjects within an acceptable tolerance range. The term "cytocompatible" means that the product can maintain the viability and growth of cell populations.
[0021] The term "biomaterial" refers to a material suitable for use in vitro, ex vivo or in vivo. As an example of in vivo use, a biomaterial is suitable for administration to a subject in need thereof. The material can be synthetic or natural. The decellularized ECM (isolated ECM) described herein is an example of a biomaterial.
[0022] The term "carrier" or "excipient" refers to a substance added to a composition that does not affect the active compound in the composition. A carrier can be a diluent. An excipient can be a substance added to a composition to facilitate administration of the composition.
[0023] The term "cosmetic" refers to products (other than pure soap) that are intended for application to the human body for cleansing, beautification, increased attractiveness, or altered appearance. Examples of cosmetic benefits may include improving the appearance of the skin, such as improving the appearance of wrinkles and fine lines, removing oil and excess sebum, reducing the appearance of skin blemishes, cleansing and conditioning the skin, toning and firming the skin, soothing irritation, and refreshing and cooling the skin.
[0024] The terms "drug", "pharmaceutical" or "therapeutic agent" mean articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and articles (other than food) intended to affect the structure or any function of the body of man or other animals.
[0025] The terms "derived," "derived from," or "derived from" refer to a product obtained from any specified source by any useful method. For example, amphibian-derived extracellular matrix (ECM) refers to ECM obtained from a member of the amphibian family.
[0026] The term "exogenous" refers to a product that originates from outside an organism, tissue, cell, organ, or subject. In contrast, the term "endogenous" refers to a product that originates from an organism, cell, tissue, organ, or subject.
[0027] The term "extracellular matrix" or "ECM" refers to a natural scaffold with a three-dimensional structure that contains biomolecules and minerals that provide biochemical support to surrounding cells. ECM includes structural and nonstructural biomolecules, such as collagen, elastin, laminin, glycosaminoglycans, proteoglycans, antimicrobial agents, chemokines, cytokines and / or growth factors. ECM can be obtained from a variety of tissue sources, including skin and non-skin tissues.
[0028] The term "decellularized extracellular matrix" or "decellularized ECM" refers to an ECM prepared by removing cells and / or inactivating cells from ECM present in multicellular organisms (e.g., amphibians or mammals). Decellularized ECM is substantially free of intact cells, lysed cells, and cellular components (including cell fragments and nuclear fragments), and thus the decellularized ECM exhibits reduced immunogenicity and can therefore be administered to a subject (e.g., a mammalian subject) as a non-toxic xenograft or biomaterial. Decellularized ECM that is "substantially free of immunogenic components" refers to an ECM in which the level of immunogenic components is insufficient to induce an adverse immune response in a subject.
[0029] The term "isolated" means separated or removed from its natural environment so that it is substantially free of components that accompany it in its naturally occurring state. For example, a cell or protein can be separated from its naturally occurring state. The term "isolated ECM" refers to a decellularized ECM.
[0030] The term "immunogenicity" refers to relating to or producing an immune response. The term "immunogenicity" refers to the ability of a foreign substance (e.g., an antigen) to stimulate an immune response in a subject. The isolated ECM described herein may have reduced immunogenicity compared to native ECM, such that it may be used as a biomaterial for a subject.
[0031] The term "native ECM" or "naive ECM" refers to naturally occurring amphibian ECM (or a corresponding ECM sample) that has not been decellularized.
[0032] The term "non-toxic" refers to a product that causes little adverse reaction or significant damage to cells and tissues in vitro or ex vivo, and / or does not cause significant adverse or undesirable reactions or significant damage to cells and tissues in the body (in vivo).
[0033] The term "prevention" refers to preventing the onset, recurrence or spread of a disease or one or more symptoms of a disease. For example, the disease can be a skin disorder. The term includes administering the products described herein prior to the onset of symptoms, particularly to a subject at risk of developing a disease (e.g., a skin disorder). The term includes inhibiting or alleviating one or more symptoms associated with a skin disorder. The term "prevention" can be used interchangeably with the term "prophylactic treatment."
[0034] The term "retaining structural and functional integrity" used in conjunction with an ECM means retaining sufficient structure and function to allow and support the use of the matrix as a substrate for cell growth in vivo, ex vivo, or in vitro. For example, an isolated ECM retains the structural and functional properties of a naturally occurring ECM, enabling its use as a biomaterial.
[0035] The terms "scaffold" and "bioscaffold" are used interchangeably and refer to a substrate on which cells can be grown in vitro, ex vivo, and / or in vivo. A scaffold or bioscaffold is an example of a biomaterial.
[0036] The term "skin condition" includes skin conditions requiring treatment with a therapeutic "drug", including diseases, imperfections and injuries, including wounds.
[0037] The term "cosmetic skin condition" includes skin conditions related to the tone, clarity, radiance, brightness and / or hydration of the skin.
[0038] The term "subject" refers to an animal, such as a mammal. Examples of mammals include humans, dogs, cats, horses, cows, goats, sheep, pigs, or non-human primates. Subjects in need of treatment or subjects in need include subjects with a disease or condition in need of treatment. Subjects in need also include subjects in need of treatment and / or prevention of skin disorders.
[0039] The term "therapeutically effective amount" refers to the amount of a product or composition (e.g., a pharmaceutical product) that provides a therapeutic benefit in the treatment, prevention, or management of a condition or disease (e.g., a skin disease, skin injury, or wound). The term "therapeutically effective amount" also includes an amount of a compound that, when administered, is sufficient to prevent the development of or alleviate to some extent one or more signs or symptoms of the disorder or disease being treated.
[0040] In the context of administering a product (e.g., a biomaterial) to a subject, the term "treating" refers to administering a product to achieve a desired clinical / medical endpoint, including alleviation of symptoms of a disease or condition. Examples of such desired endpoints associated with skin diseases or skin conditions include wound healing, tissue closure, tissue expansion, prevention of tissue adhesions, providing structural support for tissues, providing a protective barrier, and / or correction of defects. Administering a product also includes applying the product to a subject.
[0041] The term "xenospeci?c" refers to a product derived or originated from a member of another species.
[0042] The term "amphibians" refers to cold-blooded vertebrates, including frogs, toads, newts and salamanders. They have a larval stage of aquatic gill breathing, followed by an adult stage of terrestrial lung breathing. The amphibians described herein are juvenile or juvenile amphibians. Juvenile amphibians include young frogs, such as froglets, tadpoles or young anapsids in the larval stage.
[0043] The term "salamander" refers to a group of amphibians characterized by a lizard-like appearance and having a tail throughout life. There are 10 families of salamanders, including Ambystomatidae (mole salamander), Amphiumidae (Congo eel), Cryptobranchidae (giant salamander), Dicamptodontidae (Pacific giant salamander), Hynobiidae (Asiatic salamander), Plethodontidae (lungless The 10 families of salamanders are classified as Urodela or Caudata. The term "Urodele" refers to salamanders of the order Caudata, class Amphibia. Salamanders can be from the orders Caudata and Apoda.
[0044] Caudata begin life as aquatic animals in a larval state, and some undergo metamorphosis, transforming from a juvenile form with gills to an adult, terrestrial, air-breathing form with lungs. During metamorphosis, the body characteristics of an auran change in preparation for life on land. These changes include resorption of the caudal fin, thickening of the skin, development of dermal glands, and resorption of gills. Sexual maturity also occurs during this period in most aurans. However, some families of aurans are "neochronic," meaning that individuals in these families retain their juvenile aquatic form throughout their lives, even after reaching sexual maturity. The axolotl (Mexican walking fish), Ambystoma mexicanum, and / or hybrids of the Mexican and tiger axolotls are examples of neochronic salamanders. Adult axolotls do not become terrestrial amphibians, but instead remain aquatic and have gills. However, in some cases, axolotls undergo metamorphosis and transform into a terrestrial form.
[0045] Axolotls have the ability to completely regenerate lost or damaged body parts, including organs, limbs, and parts of the central nervous system, throughout their lives. Aquatic axolotls undergo rapid re-epithelialization during wound healing and limb regeneration, both of which are scarless processes. Similarly, metamorphosing terrestrial axolotls retain many features of larval skin and also exhibit scarless wound healing, but at a slower rate than their aquatic pre-metamorphotic counterparts. The axolotl wound healing process resembles the scarless healing of mammalian fetal and embryonic wounds. Such wounds exhibit re-epithelialization and basement membrane reformation, which occurs more rapidly than corresponding events in postnatal mammals. Furthermore, similar to the human amniotic membrane (AM), the salamander ECM is rich in growth factors that facilitate wound healing.
[0046] ECM is a three-dimensional network of extracellular macromolecules and minerals including collagen, enzymes, glycoproteins and hydroxyapatite, which provides structural and biochemical support for surrounding cells. ECM can include a combination of fibrous and network collagen. Examples of various types of collagen, such as one or more of type I, II, III, IV, V and VI collagen. ECM can also include elastin and / or elastic fibers. ECM can also include laminin, fibronectin, hyaluronic acid, chondroitin sulfate or both, and / or one or more proteoglycans, glycoproteins, glycosaminoglycans or any combination thereof. The composition and structure of ECM play an important role in the healing process, because the ECM composition can build a scaffold, providing the structural framework of the matrix required for the healing process. In addition, ECM components also participate in stimulating the adhesion and migration of cells in the healing process, and mediate the interaction between cells, between cells and matrix or between ECM proteins in the healing process. In addition, ECM components also act as a reservoir and regulator for cytokines and growth factors to regulate wound repair activities. However, ECM contains cells and genetic material that need to be removed before use as biomaterials because the cells and genetic material may induce adverse immune responses.
[0047] Decellularization of ECM is the removal of cells and cellular components from the ECM of a biological sample (e.g., tissue) while retaining ECM proteins and native ECM architecture or structure for effective use as a biomaterial. The present disclosure describes a novel method for decellularizing amphibian ECM (e.g., anuran ECM) for use in preventing and / or treating and curing various conditions, including skin conditions. Compared to known methods for decellularizing ECM (which may involve the use of cross-linking agents and other irritating agents), the methods described herein use milder agents but provide decellularized amphibian ECM containing fewer cells and cell fragments, thereby enabling the decellularized ECM to be used in vitro, ex vivo, and / or in vivo without causing undesirable side effects.
[0048] The method of decellularizing amphibian ECM comprises harvesting or obtaining an amphibian sample, washing the sample, and incubating the sample with one or more proteases and one or more nucleases. In embodiments, the method of decellularizing amphibian ECM comprises harvesting an amphibian sample, washing the sample, incubating the sample with one or more proteases, washing the protease-treated sample, incubating the washed protease-treated sample with one or more nucleases to obtain an isolated ECM, which can be used as a biomaterial in vitro, ex vivo, and / or in vivo.
[0049] Amphibian samples include any biological sample from amphibians, especially from young amphibians (e.g., young frogs or young-state-persistent urodendrons), which contains ECM and can be decellularized and used. Biological samples can include any amphibian tissue, such as connective tissue, adipose tissue, bone, plasma, skin, cartilage, tendon, dura mater and fascia. Other tissues include dermis, basement membrane and epithelial tissue, such as basement membrane or epithelial tissue lining the body cavity, such as the wall mesothelial tissue of the thorax, abdominal cavity and pericardium. In embodiments, biological samples are tissues from young amphibians (e.g., young frogs or young-state-persistent urodendrons). Biological samples can be fresh samples or thawed frozen samples. Samples can be obtained from any urodendron species (including axolotls). In embodiments, samples are obtained from the skin of axolotls.
[0050] The amphibian sample is obtained or harvested from a juvenile amphibian (e.g., a neotenic anuran or a young frog). The sample is surgically removed from the tissue of the juvenile amphibian. The sample can be a full-thickness explant of various shapes and sizes. The size of the sample can be 5×5 centimeters (cm) or larger. The sample is cleaned and prepared for decellularization.
[0051] The decellularization method described herein includes briefly rinsing the sample with one or more solutions (including water or a buffer solution) before protease treatment, and washing with a detergent solution under stirring. Examples of buffer solutions include phosphate buffered saline (PBS), Dulbecco's PBS (DPBS), tris buffered saline (TBS) and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Detergents include non-denaturing nonionic and anionic surfactants that are gentle to the ECM and easy to use, such as can be used at room temperature without increasing or decreasing temperature or pressure. It has been found that nonionic surfactants such as Triton TM X-100 (2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol) and Triton TM X-100 Reduced (polyoxyethylene (10) isooctyl cyclohexyl ether) and secondary alcohol ethoxylates such as TERGITOL TM (Secondary alcohol ethoxylates) such as TERGITOL TM 15-2-9 (polyethylene glycol ether surfactant) and TERGITOL TM TMN-10 (trimethylnonyl polyethylene glycol, polyethylene glycol trimethylnonyl ether) and anionic detergents such as N-laurylsarcosine (NLS), laurylsarcosine potassium, cholate, deoxycholate, sodium dodecyl sulfate (SDS) are mild detergents useful for decellularization of amphibian biological samples. Other nonionic surfactants include polyoxyethylene sorbitan fatty acid esters or Tweens, such as Tween 20, Tween 40, Tween 60 or Tween 80.
[0052] The sample can first be rinsed with water or a buffer solution at room temperature for 3 to 10 minutes (min), and then washed with a detergent at 37°C with agitation. Exemplary washing conditions for detergents include: washing a 5×5 cm amphibian sample twice with a concentration of 0.1% to 1.0% v / v detergent in 20 to 30 mL of a buffer (e.g., DPBS) for 3 to 12 hours (hr) each time, each time at 37°C with agitation at 90-120 revolutions per minute (RPM). In an embodiment, the sample is briefly washed with DPBS at room temperature for 5 minutes, then washed with Triton (e.g., Triton X-100 or Triton X-100Reduced) or NLS at 37°C with agitation at 100 RPM for 6 hours, followed by a 5 minute rinse with a buffer solution (e.g., PBS or DPBS) at room temperature, and then treated with one or more proteases.
[0053] The sample can also be washed with a non-detergent solution containing latracunlin (Lat) or cytochalasin instead of a detergent solution. Lat is a cytochalasin, which is an actin depolymerizing agent. They bind to actin monomers near the nucleotide binding cleft and prevent actin monomer polymerization. Examples of Lat include Lat A and Lat B. Examples of cytochalasins include cytochalasins A, B, C, D, E, F, H and J. Lat has a potency in the nanomolar range. An exemplary non-detergent process using Lat for a 5×5 cm tissue sample is as follows: the sample is incubated in 100 ml of 50 nanomolar (nM) Lat (e.g., Lat B) in high glucose DMEM at 37° C. for 2 hours, washed with 100 ml of double distilled water for 15 minutes, incubated with 100 ml of 0.6 M potassium chloride for 90 minutes, incubated in 100 ml of 1.0 molar (M) potassium iodide for 90 minutes, washed with 200 ml of distilled water overnight, incubated with potassium chloride, incubated with potassium iodide, and washed with distilled water overnight. Washes and incubations with high ionic solutions are performed at room temperature.
[0054] The washed amphibian sample is then incubated with one or more proteases at 37°C for about one to two hours to remove the epidermis and disrupt the attachment of cells to the dermal matrix. The concentration of the protease is at least 1 unit enzyme / mL solution or 2 to 10 units / mL, 2 to 7 units / mL, 2 to 5 units / mL, or 2 to 4 units / mL solution. The one or more proteases used to treat the amphibian sample include amino endopeptidases, which are relatively mild, dissociate well at physiological temperature and pH, and can maintain the integrity of the cell membrane, which makes the method easier to perform. Examples of amino endopeptidases include dispase, such as dispase I and dispase II, trypsin, papain, and collagenase. In an embodiment, the protease used to treat the sample is dispase II. It has been found that dispase II has a mild proteolytic effect, helps maintain cell membrane integrity, and is easy to use because it can be used at physiological temperature and pH. In an embodiment, a 5×5 cm tissue sample is incubated with 2 units of dispase II / mL DPBS at 37°C for 90 minutes. In an embodiment, the dispase is dispase II (CAS #42613-33-2).
[0055] The protease treated sample is then briefly rinsed with one or more solutions including water or a buffered solution at room temperature. In an embodiment, the protease treated sample is rinsed with buffered saline (eg, PBS or DPBS) for 5 minutes.
[0056] After briefly rinsing with PBS or DPBS, the sample treated with protease is then incubated with one or more nucleases at 37°C under 90 to 120RPM stirring for 3 to 12 hours. The concentration of nuclease is at least 30 units / ml solution, or 40 to 100 units / ml, 40 to 75 units / ml, 40 to 60 units / ml, or 40 to 50 units / ml solution. In this step, non-specific DNA / RNA endonucleases are used to remove nucleic acids from the sample. Examples of non-specific endonucleases include benzonuclease and turbonuclease. Other nucleases include recombinant DNA nuclease, pulmozyme, and a combination of DNases and RNases. In embodiments, the washed protease treated sample is treated with 40 units / ml omnipotent nuclease for 6 hours. After nuclease treatment, the sample is briefly rinsed with a buffer solution (eg, PBS or DPBS) at 37° C., followed by a wash with a buffer solution (eg, PBS or DPBS) at 37° C. with shaking at 100 RPM for 24 hours. In an embodiment, the nuclease is benzonase (CAS#9025-65-4).
[0057] In an embodiment, the sample is washed with Triton X-100Reduced, treated with dispase II, treated with universal nuclease, and washed with DPBS. Between each of these steps, the sample can be briefly rinsed with buffered saline (e.g., PBS or DPBS) for five minutes, using three times the volume of the solution in each step.
[0058] Optionally, the isolated ECM after nuclease treatment and washing can be stored, dialyzed, disinfected, sterilized, micronized, dehydrated (lyophilized) and / or converted to other forms for suitable use. After nuclease treatment, the isolated ECM can be stored at -20°C. The isolated ECM can also be stored in 10% formalin neutral buffer.
[0059] The separated ECM can be sterilized using gamma radiation, electron beam (e-beam), glutaraldehyde, ethylene oxide, peracetic acid (PAA), ethanol or a CO2-based technology. In an embodiment, the separated ECM is sterilized using a CO2-based technology that can sterilize soft materials without compromising the effectiveness of the material. The separated ECM can be micronized by screening, cryogenic grinding, chopping, spray drying, jet grinding or supercritical fluid (SCF) technology. The separated ECM can also be freeze-dried at low temperatures to remove water, which can be achieved in a desiccator or a low-temperature vacuum furnace.
[0060] The isolated ECM can be micronized to a particle size of about 1 to 1000 microns, 1 to 900 microns, 1 to 800 microns, 1 to 700 microns, 1 to 600 microns, 1 to 500 microns, 1 to 400 microns, 1 to 300 microns, 1 to 200 microns, 100 to 300 microns, 100 to 250 microns, 100 to 200 microns, 100 to 150 microns, or 100 to 125 microns. In embodiments, the size of the particles is about 100 to 500 microns. The micronized particles can be immediately dehydrated by lyophilization and stored at room temperature after lyophilization.
[0061] Lyophilization can include one or more cycles of freezing under vacuum and low temperature drying under vacuum. Examples of temperatures for freezing the isolated ECM in lyophilization can include -25°C to -60°C, -25°C to -50°C, -25°C to -45°C, -30°C to -45°C, -35°C to -45°C, or -45°C. Examples of temperatures for drying isolated ECM samples in lyophilization can include 10°C to -50°C, 10°C to -45°C, 10°C to -40°C, 5°C to -40°C, 5°C to -30°C, 5°C to -25°C, 0°C to -25°C, -40°C, -25°C, or 5°C. Examples of pressures for freezing and / or drying isolated ECM samples during freeze drying include 25 mTorr to 375 mTorr, 25 mTorr to 360 mTorr, 50 mTorr to 360 mTorr, 75 mTorr to 360 mTorr, 100 mTorr to 360 mTorr, 150 mTorr, to 325 mTorr, 175 mTorr, to 300 mTorr, 200 mTorr to 300 mTorr, 225 mTorr to 275 mTorr, 360 mTorr, 300 mTorr, 250 mTorr, 100 mTorr, or 50 mTorr. The length of time for drying and / or freezing can be 5 minutes to 800 minutes, 5 minutes to 750 minutes, 5 minutes to 720 minutes, 5 minutes to 400 minutes, 90 minutes to 350 minutes, 10 minutes to 720 minutes, 5 minutes, 120 minutes, 300 minutes, or 720 minutes. In an embodiment, the separated sample is freeze-dried in a first stage by freezing at 360 mTorr for 5 minutes, followed by a first stage of drying at -40°C for 120 minutes at 100 mTorr, at -25°C for 300 minutes at 50 mTorr, and at -25°C for 720 minutes at 250 mTorr, followed by a second stage of drying at 5°C for 120 minutes at 300 mTorr.
[0062] Following decellularization, the isolated ECM can be analyzed by staining to visualize the structural integrity of the decellularized ECM as well as the removal of cells by light microscopy and to quantify the amount of DNA. Staining methods include hematoxylin and eosin staining (H&E staining) and DAPI (4'6-diamidino-2-phenylindole). Hematoxylin is a basic dye that stains acidic components of cells (e.g., nuclei), while eosin is an acidic dye that stains alkaline components of cells (e.g., cytoplasm). DAPI is a blue fluorescent DNA dye. Surprisingly, it was found that more than 70% of the cells were removed from the isolated ECM, but the ECM architecture remained intact (see Figures 1A-1F ). In addition, the novel decellularization method described herein removes a large amount of DNA from cells. The isolated ECM contains less than 10 ng of DNA, which is approximately less than 10% of the total DNA in the native (original) ECM (see Figure 2A-2BIn addition, the length of the residual DNA fragments in the isolated ECM is less than 300 bp (see Figure 3A-3B ), while the length of DNA in natural ECM is greater than 250 kilobases (kbp).
[0063] The disclosure describes a kind of ECM of separation, it removes its cell (natural cell) more than 70%, but it has the structure and / or functional framework of natural amphibian ECM.The ECM of separation removes its natural cell greater than 99%, 95% to 99%, 90% to 99%, 71% to 99%, 75% to 95%, 80% to 90% or 80% to 85%.The ECM of separation removes its natural cell greater than 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.The ECM of separation contains less than 30% of its natural cell.The ECM of separation removes its natural cell of 1% to 29%, 5% to 25%, 10% to 20% or 15% to 20%. The isolated ECM contains less than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20% or 25% of its native cells. The isolated ECM contains undetectable amounts of its native cells.
[0064] The amount of residual DNA in the isolated ECM described herein is less than 1 ng / μl (ng DNA per microliter of extract) or only 1 to 10 ng / μl, 2 to 9 ng / μl, 3 to 8 ng / μl, 3 to 7 ng / μl, 3 to 6 ng / μl, 3 to 5 ng / μl, 3 to 4 ng / μl, 2 to 3 ng / μl, 4 to 5 ng / μl, 5 to 6 ng / μlμl, 6 to 7 ng / μl, 7 to 8 ng / μl, 2.5 ng / μl, 3 ng / μl, 3.5 ng / μl, 4 ng / μl, 4.5 ng / μl, 5 ng / μl, 5.5 ng / μl, 6 ng / μl, 6.5 ng / μl, 7 ng / μl, 7.5 ng / μl or 8.0 ng / μl (ng DNA per microliter of extract). In contrast, the native (original) ECM contains DNA in an amount of 100 ng / μl (DNA per microliter of DNA extraction solution). Compared to the native ECM, the amount of residual DNA in the separated ECM is less than 1% of the amount of DNA in the native ECM or is only 1% to 10%, 2% to 9%, 2% to 5%, 3% to 8%, 3% to 7%, 3% to 6%, 3% to 5%, 3% to 4%, 2% to 3%, 4% to 5%, 5% to 6%, 6% to 7%, 7% to 8%, 1%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5% or 8.0% of the amount of DNA in the native ECM. The amount of residual DNA in the separated ECM is not detectable.
[0065] The amount of DNA in the isolated ECM described herein is less than 20 ng / mg dry ECM. In embodiments, the amount of DNA in the isolated DNA is 10 to 19 ng / mg, 10 to 18 ng / mg, 10 to 17 ng / mg, 10 to 16 ng / mg, 10 to 15 ng / mg, 19 ng / mg, 18 ng / mg or 17 ng / mg dry ECM.
[0066] In addition, the length of the residual DNA fragments in the separated ECM is less than 300bp (see Figure 3). The length of the residual DNA fragments in the separated ECM is undetectable, or the length is less than 50bp, or the length is between 50 to 300bp, 60 to 290bp, 70 to 280bp, 80 to 270bp, 90 to 260bp, 50 to 250bp, 100 to 250bp, 100 to 240bp, 100 to 230bp, 100 to 220bp, 100 to 210bp or 100 to 200bp. In embodiments, the length of the residual DNA fragments in the separated ECM is less than 250bp. Therefore, compared with the natural ECM having a length greater than 250kbp, the length of the residual DNA fragments in the separated ECM is quite small.
[0067] Decellularization method as described herein provides a kind of ECM of separation, wherein its interstitial structure is basically intact and has biological activity.The ECM of separation has enough structural and functional characteristics and / or reduced immunogenicity, so that it can be used as a biomaterial in vitro, in vitro and / or in vivo.The ECM of separation has basic natural structure, so that cells can grow thereon.The ECM of separation can be used as a scaffold for cell adhesion, proliferation, differentiation, regeneration and tissue development in vitro, in vitro and / or in vivo, without causing any adverse reaction.The ECM of separation is substantially free of immunogenic components, so it can be applied to a subject.The ECM of separation is substantially free of cell and nuclear fragments, and is basically clean, and has reduced immunogenicity, so it can be used as a biomaterial.ECM is substantially free of cell fragments and nuclease fragments, such as DNA.
[0068] In isolated ECM, the structural and functional properties of the native ECM are intact. ECM components used for wound healing and treatment and prevention of skin disorders are retained in the isolated ECM.
[0069] The present disclosure describes ECM compositions and composite materials comprising isolated ECM. In addition to the isolated ECM, the composition may also include one or more carriers or excipients. Examples of carriers and excipients include saline, emulsions, mixtures of organic solvents and water, calcium carbonate, calcium phosphate, various sugars and starch types, cellulose derivatives, gelatin, vegetable oils, vaseline, lanolin, mineral oil, polydimethylsiloxane, humectants and polyethylene glycol. Examples of humectants include glycerol, lecithin and propylene glycol. In embodiments, the compositions described herein include cosmetic compositions or pharmaceutical compositions, which include one or more cosmetically or pharmaceutically acceptable carriers or excipients, respectively.
[0070] The compositions described herein may include one or more pharmaceutical agents, such as one or more therapeutic agents. Examples of therapeutic agents include known drugs such as retinoic acid, corticosteroids, antifungal agents, antiviral agents, antibiotics, antiseptics, local anesthetics, and antitumor agents.
[0071] The compositions described herein may include one or more medicaments, such as one or more cosmetic agents. Examples of cosmetic agents include antioxidants, peptides, alpha or beta hydroxy acids, retinol, vitamins, plant extracts, skin cleansers (e.g., arbutin), moisturizers (e.g., hyaluronic acid), emollients, carbohydrates, glycoproteins, and / or polymers. One or more medicaments may include a combination of medicaments. For the separated ECM, the medicament may be exogenous or heterologous.
[0072] Examples of one or more peptides and proteins include growth factors, cytokines and chemokines. Examples of growth factors include fibroblast growth factor (FGF), including acidic FGF, basic FGF, FGF8 and FGF10; ciliary neurotrophic factor (CNTF); epidermal growth factor (EGF); granulocyte-macrophage colony stimulating factor (GM-CSF); hepatocyte growth factor (HGF); insulin-like growth factor 1 and 2 (IGF-1 and IGF-2); keratinocyte growth factor (KGF); nerve growth factor (NGF); neurotrophic factors, such as neurotrophin-3, neurotrophin-4, neurotrophin-5; platelet-derived growth factor (PDGF); vascular endothelial growth factor (VEGF); matrix-derived factor 1α (SDF-1α); and transforming growth factor-α and -β (TGF-α and TGF-β). Examples of cytokines and chemokines include tumor necrosis factor-α (TNF-α), interleukin-1α and β (IL-1α and IL-1β), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-18 (IL-18), CCL2, CCL3, CCL5, CXCL1, CXCL4, CXCL5, CXCL7, CXCL8, and CXCL12. Examples of beauty peptides include acetyl hexapeptide, acetyl tetrapeptide, palmitoyl pentapeptide, and palmitoyl oligopeptide.
[0073] Examples of one or more therapeutic agents include antibacterial agents and anti-inflammatory agents. Examples of antibacterial agents include antibiotics, such as penicillin, streptomycin, amoxicillin, cephalexin, clindamycin, dicloxacillin and doxycycline. Other antibacterial agents include antimicrobial peptides, silver salts, clotrimazole, miconazole and ketoconazole. Examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs (NSAIDs), such as salicylic acid, ibuprofen, naproxen, colchicine, fenoprofen, sulindac, diflunisal, diclofenac, indoprofen and sodium salicylamide.
[0074] Examples of cosmetic agents include one or more glycoproteins, including proteoglycans (which are proteins covalently linked to glycosaminoglycans (GAGs)), antioxidants, ascorbic acid, vitamin C, alpha hydroxy acids (AHAs), beta hydroxy acids (BHAs), exfoliants, skin whitening agents, light diffusers, UV absorbers, sunscreens, moisturizers, anti-wrinkle ingredients, and oil absorbers. Examples of AHAs include glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid. Examples of BHAs include salicylic acid.
[0075] Compositions as described herein can also include one or more natural and / or synthetic polymers. Natural polymers can be from animal sources or non-animal sources, such as plant sources. Examples of natural polymers include natural polymers, such as collagen, chitosan, alginate, glycosaminoglycans, fibrin and hyaluronic acid. Examples of synthetic polymers include polyethylene, polyethylene glycol (PEG), polyethylene terephthalate (PET or PETE), polytetrafluoroethylene (PTFE), polylactic acid (PLA), polyglycolic acid (PGA), polyethylene glycol (PEG), poly (ethylene glycol) diacrylate (PEG diacrylate), poly (hydroxy acid), polydioxanone, polycaprolactone, poly (orthoester), poly (anhydride), polyphosphazene, poly (amino acid), pseudo poly (amino acid), conductive polymers (such as polyacetylene, polypyrrole, polyaniline), polyurethane, polystyrene and nitinol.
[0076] The polymer of the composition described herein can be biocompatible, biodegradable and / or bioabsorbable, and can be a random copolymer, block copolymer, or a mixture of monomers, homopolymers, copolymers and / or heteropolymers comprising these monomers. Exemplary biodegradable or bioabsorbable polymers include polylactide, polyglycolide, polycaprolactone, polydioxane and random and block copolymers thereof. Biodegradable and / or bioabsorbable polymers can include monomers selected from the group consisting of glycolide, lactide, dioxanone, caprolactone, trimethylene carbonate, ethylene glycol and lysine. Biodegradable and / or bioabsorbable polymers can include bioabsorbable and biodegradable linear aliphatic polyesters, such as polyglycolide (PGA) and its random copolymer poly (glycolide-to-lactide) (PGA-co-PLA). Other examples of suitable biocompatible polymers include polyhydroxyalkyl, methacrylate, ethyl methacrylate, polyvinylpyrrolidone and polyacrylamide. Other suitable bioabsorbable materials are biopolymers, including collagen, gelatin, alginate, chitin, chitosan, fibrin, hyaluronic acid, dextran, polyamino acids, polylysine and copolymers of these materials. Any combination or mixture of the polymers and copolymers of the above examples can also be included in the composition.
[0077] The compositions described herein may also contain protectants, adsorbents, demulcents, emollients, preservatives, antioxidants, humectants, buffers, solubilizers, skin penetration enhancers, and surfactants.
[0078] Any skin penetration enhancer can be added to the composition, as long as the skin penetration enhancer is safe and can effectively promote the desired substance in the isolated ECM to pass through the skin membrane. Examples of skin penetration enhancers include dimethyl sulfoxide (DMSO), monoglycerides, C10-C20 fatty acid esters, including ethyl palmitate and isopropyl myristate; acyl lactylates, such as caproyl lactylic acid and lauroyl lactylic acid; dimethyl lauramide; dodecyl (lauryl) acetate; lactic acid esters, such as lauryl lactylate and myristyl lactylate; monoalkyl ethers of polyethylene glycol and their alkyl or aryl carboxylates and carboxymethyl ethers, such as polyethylene glycol-4 lauryl ether (Laureth-4) and polyethylene glycol-2 lauryl ether (Laureth-2); myristyl alcohol-3 (Myreth-3), myristyl sarcosine and methyl laurate; polypropylene glycol, polyethylene glycol, lecithin, urea, amino acids, 1-dodecylhexahydro-2H-azepin-2-one (Azone), oleic acid, linoleic acid, isopropyl linoleate, oleyl alcohol, 1-dodecyl-azacycloheptane-2-one, butylene glycol, 2-(2-ethoxyethoxy)ethanol (Transcutol).
[0079] The isolated ECM and compositions described herein can be prepared into dry powders, solutions, pastes, liquids, extracts, creams, lotions, serums, emollients, ointments, dispersions or emulsions. The isolated ECM and compositions can be prepared into various suitable shapes and sizes because they can be molded, laminated, homogenized and reconstructed. They can be formed into two-dimensional or three-dimensional shapes. They can be formed into thin sheets, meshes, grafts, plugs or any shape or form for use. The thin sheets can include a backing with or without an adhesive. The backing can be biodegradable or non-biodegradable. Two or more thin sheets can be laminated together or connected in some way. The thin sheets can be oriented in the same direction, in different directions or at an angle. There can be two to fifteen thin sheet layers. The thin sheets can be from amphibian ECMs from different sources.
[0080] In embodiments, the powder comprising micronized particles can be reconstituted with water, a buffered solution, or any suitable liquid and / or carrier to form a solution, paste, liquid, extract, cream, lotion, serum, emollient, ointment, dispersion, or emulsion. The solution can be a buffered solution, similar to the solution used for the decellularization process.
[0081] It has been shown that the isolated ECM described herein has therapeutic or cosmetic activity, which depends on the degree of decellularization, concentration and / or final composition. Therefore, the isolated ECM therapeutic composition described herein can be used in vitro, in vitro and / or in vivo. Because the isolated ECM has various biological activities that participate in the regenerative cell process, the isolated ECM and composition described herein can be used as biomaterials for wound healing, tissue regeneration, as a cell growth scaffold, and for the treatment and prevention of various skin disorders. The biomaterial can be made into an implant for regenerating tissue. Since the isolated ECM can also be used as a scaffold, cells can grow on the ECM to enhance the regeneration and wound healing of tissues and organs. The biomaterial can also be applied to, coated on and / or infused in an implant or medical device to be applied to a subject. The medical device can be a patch, a bandage or any suitable device for delivering a biomaterial. Therefore, the biomaterial can be used as the material of any xenotransplant or xenograft.
[0082] Biomaterials can also be used as systems or devices for delivering agents to tissues and organs for wound healing, tissue regeneration, and treatment and / or prevention of various skin disorders. Endogenous agents in biomaterials, such as growth factors, can be delivered by immediate release or controlled release. In addition, exogenous or xenobiotic agents added to biomaterials can be delivered by immediate release or controlled release.
[0083] Carriers for immediate release or sustained release formulations include polymers. The polymers can be biodegradable, and / or bioabsorbable. For example, for controlled release, the biomaterial can be coated with a polymer such as an acrylic acid polymer, an acrylic acid / methacrylic acid copolymer, cellulose acetate phthalate (CAP), and Ethocel TM For immediate release, the biomaterial can be coated with cellulosic polymers such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), methylcellulose (MC), and sodium carboxymethylcellulose (NaCMC); vinyl derivatives such as polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinyl alcohol (PVA), and polyvinyl alcohol-polyethylene glycol copolymer; acrylic polymers such as or a glycol, such as polyethylene glycol.
[0084] The isolated ECM and compositions described herein can be prepared into preparations for treating and / or preventing various skin conditions, including inflammatory and cancerous skin conditions. The preparation can be in the form of a dry powder, solution, paste, liquid, extract, cream, lotion, essence, emollient, ointment, dispersion or emulsion. The amount of the isolated ECM in the preparation is 0.001% to 5.0% w / v, 0.01% 4% or 0.05% to 1.0% w / v. The preparation can be placed on a bandage (e.g., a non-stick bandage) or impregnated therein for application to a subject.
[0085] Examples of skin disorders to be treated include acne, actinic keratosis, blisters, cellulitis, cold blisters, hives, impetigo, keratosis pilaris, melasma, moles, ringworm, chronic idiopathic urticaria, vitiligo, and warts. Examples of inflammatory skin disorders include psoriasis; dermatitis, such as contact dermatitis, atopic dermatitis (eczema), seborrheic dermatitis, nummular dermatitis, systemic exfoliative dermatitis, stasis dermatitis, chronic simple lichen; hair follicle and sebaceous gland diseases, such as acne, rosacea and hypertrophic rosacea, perioral dermatitis, and pseudofolliculitis barbae; and inflammatory reactions, such as drug eruptions, erythema multiforme, erythema nodosum, and annular granuloma. Examples of cancerous skin disorders include basal cell carcinoma, melanoma, and squamous cell carcinoma. Other skin conditions that may require treatment include fine lines and / or wrinkles, aging, redness, abrasions, burns, cuts, infections, shaving rash, scarring, uneven skin tone, pain, stretch marks, skin elasticity and / or firmness, skin hydration, and hyperpigmentation.Burns include acute thermal burns, including first, second, or third degree burns.
[0086] The isolated ECM and compositions described herein can also be used in skin care regimens to protect the skin from damage including UV rays and environmental pollution, and can be used as cosmetic agents to improve the appearance of the skin.
[0087] The isolated ECM and compositions described herein can be topically applied to the target site, or by injection, implantation, microneedle or radiofrequency microneedle, or applied to the target site using an ablative fractional laser. The isolated ECM and compositions described herein can be applied to the subject before, during, or after dermatological or cosmetic surgery (e.g., dermabrasion, microdermabrasion, and ablative laser surface resurfacing). Dermatological or cosmetic surgery includes surgery to remove at least one cell of the stratum corneum. The isolated ECM and compositions described herein can also be delivered as an injection or with a dermal or subdermal implant, such as a volume filler, hyaluronic acid, or other dermal matrix protein (including collagen or elastin, whether naturally occurring, bioengineered, or recombinantly produced). The isolated ECM and compositions described herein can be applied alone or in combination with one or more agents described herein (e.g., growth factors, peptides, or proteins). The isolated ECM can also be applied with a toxin (e.g., botulinum toxin).
[0088] The isolated ECM and compositions described herein can reduce inflammation, reduce scarring, reduce keloid formation, reduce or lessen the severity of scar and keloid formation, and / or reduce healing time for various dermatological and cosmetic procedures. The isolated ECM and compositions described herein can also be used to restore lost dermal matrix or subdermal volume.
[0089] The present disclosure describes kits containing the isolated ECM or compositions described herein for various uses described herein. The kits may contain sterilized isolated ECM or compositions thereof in any shape and form. The kits may contain solutions for reconstituting the ECM for use. The kits may contain devices for administering the isolated ECM or compositions to a subject. The kits may contain implants to be coated with the ECM or compositions prior to implantation into a subject. The kits may contain components for various uses described herein.
[0090] The present disclosure also describes medical devices containing the isolated ECM or compositions described herein for various uses described herein. A medical device can be a material or object used directly or indirectly to apply the isolated ECM or compositions described herein. For example, a medical device can be used to apply the isolated ECM or compositions described herein to the skin of a subject.
[0091] Unless otherwise specified herein or the context is clearly contradictory, all methods described herein can be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "for example") provided herein is intended only to better illustrate the present invention and does not limit the scope of the present invention. Any language in the specification should not be interpreted as indicating any unclaimed element essential to the practice of the present invention.
[0092] Numbers used in the specification and claims indicating ranges or quantities of ingredients, components, reaction conditions, and the like are to be understood as modified by the term "about". When greater clarity is required, the term "about" when used in conjunction with a specified value or range has the meaning reasonably assigned by one skilled in the art, i.e., to mean slightly greater than or slightly less than the specified value or range, within ±20% of the specified value; ±15% of the specified value; ±10% of the specified value; ±5% of the specified value; ±4% of the specified value; ±3% of the specified value; ±2% of the specified value; ±1% of the specified value; or any percentage between ±1% and 20% of the specified value.
[0093] It will be understood by those of ordinary skill in the art that each embodiment disclosed herein may include or consist of the elements, steps, ingredients or components specifically indicated therein. Therefore, the term "includes" or "comprising" should be interpreted as: "includes, consists of or consists essentially of..." The transitional term "includes" or "comprising" means including but not limited to, and allows the inclusion of unspecified elements, steps, ingredients or components, even if the number is large. The transitional phrase "consisting of..." excludes any unspecified elements, steps, ingredients or components. The transitional phrase "consisting essentially of..." limits the scope of the embodiment to the specified elements, steps, ingredients or components, as well as those elements, steps, ingredients or components that do not have a substantial effect on the embodiment. In the embodiment, evidence that a step has no substantial effect is that there is no statistically significant reduction in the process step of removing cell debris (e.g., DNA) from the sample. The embodiment having no substantial effect may include no statistically significant improvement in wound healing, cell growth, cell repopulation, cell attachment, cell proliferation or cell migration using the separated ECM.
[0094] The description of the numerical range herein is intended only as a shorthand method for individually quoting each individual value falling within the range. Unless otherwise specified herein, each individual value is incorporated into the specification as if it were individually described herein. The description of the range should be deemed to explicitly disclose all possible subranges and individual values within the range. For example, the description of a range such as 1 to 6 should be deemed to explicitly disclose subranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, and individual numbers within the range, such as 1, 2, 2.5, 2.7, 3, 4, 5, 5.1, 5.3, 5.8 and 6. In addition, any range cited herein is inclusive.
[0095] The grouping of alternative elements or embodiments of the invention disclosed herein is not to be construed as limitations. Each group member may be referenced and claimed individually or in any combination with other members of the group or other elements found herein.
[0096] The following exemplary embodiments and examples illustrate the exemplary methods provided herein. These exemplary embodiments and examples are not intended to, nor should be construed as, limiting the scope of the present disclosure. Obviously, these methods can be implemented in a manner different from that specifically described herein. According to the teachings of this article, many modifications and variations can be made, and therefore, these modifications and variations are within the scope of the present disclosure. Exemplary embodiments
[0097] The following are exemplary embodiments: 1. An isolated amphibian ECM, wherein the ECM is decellularized, comprises intact native ECM structure, and is characterized by having: less than 1% to 10% of the total DNA present in the corresponding native ECM sample; Residual DNA fragments less than 300 bases (bp); and / or More than 70% of the ECM was decellularized. 2. The ECM of embodiment 1, wherein the ECM is characterized by having less than 1%, 2% to 9%, 2% to 5%, 3% to 8%, 3% to 7%, 3% to 6%, 3% to 5%, 3% to 4%, 2% to 3%, 4% to 5%, 5% to 6%, 6% to 7%, 7% to 8%, 1%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5% or 8.0% of the total amount of DNA present in the corresponding native ECM sample. 3. The ECM of embodiment 1 or 2, wherein the ECM is characterized by having residual DNA fragments of less than 50 bp, 50 to 300 bp, 60 to 290 bp, 70 to 280 bp, 80 to 270 bp, 90 to 260 bp, 100 to 250 bp, 100 to 240 bp, 100 to 230 bp, 100 to 220 bp, 100 to 210 bp, or 100 to 200 bp in length. 4. The ECM of any one of embodiments 1 to 3, wherein the ECM is characterized by having residual DNA fragments less than 250 bp in length. 5. The ECM of any one of embodiments 1 to 4, wherein the ECM is characterized by having greater than 99%, 95% to 99%, 90% to 99%, 71% to 99%, 75% to 95%, 80% to 90%, or 80% to 85% of its cells removed. 6. The ECM of any one of embodiments 1 to 5, wherein the ECM is in the form of a dry powder, paste, solution, extract, cream, lotion, dispersion or emulsion. 7. The ECM of any one of embodiments 1 to 6, wherein the ECM is obtained from a juvenile amphibian, optionally comprising a froglet, a tadpole, anuran, or a juvenile anapsid in the larval stage. 8. The ECM of any one of embodiments 1 to 7, wherein the ECM is obtained from a neotenic anuran. 9. A composition comprising a carrier and the ECM according to any one of embodiments 1 to 8. 10. The composition of embodiment 9, wherein the composition is a pharmaceutical composition or a cosmetic composition, and optionally, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and wherein the cosmetic composition comprises a cosmetically acceptable carrier. 11. The composition of embodiment 9 or 10, wherein the composition further comprises one or more agents, and optionally, wherein the one or more agents are xenogeneic to the isolated ECM. 12. A composition according to any one of embodiments 9 to 11, wherein the composition further comprises one or more pharmaceutical agents, wherein the one or more pharmaceutical agents are peptides, proteins, drugs, nutrients, retinoids, emollients, steroids, carbohydrates, glycoproteins, polymers or combinations thereof. 13. The composition of any one of embodiments 9 to 12, further comprising one or more growth factors, cytokines, chemokines, or a combination thereof. 14. A composition according to any one of embodiments 9 to 13, wherein the composition further comprises one or more polymers, and optionally, wherein the one or more polymers are synthetic or natural polymers or copolymers. 15. A method of decellularizing amphibian ECM, wherein the method comprises harvesting a biological sample from an amphibian, washing the sample with a detergent solution, and treating the sample with one or more proteases and one or more nucleases to obtain isolated ECM. 16. A method according to embodiment 15, wherein the method includes harvesting a biological sample from an amphibian, rinsing the sample with a solution, washing the sample with a detergent solution, treating the sample with a protease, rinsing the sample after the protease treatment, and treating the rinsed protease-treated sample with a nuclease to obtain an isolated ECM, and optionally, further washing the isolated ECM. 17. The method according to embodiment 15 or 16, wherein the method comprises: flushing with water or a buffer solution, optionally with phosphate buffered saline (PBS) or Dulbecco's phosphate buffered saline (DPBS). 18. The method of any one of embodiments 15 to 17, wherein the sample is washed with a detergent solution comprising one or more surfactants. 19. The method according to any one of embodiments 15 to 18, wherein the sample is washed with a detergent solution comprising one or more non-ionic surfactants or anionic surfactants. 20. The method according to any one of embodiments 15 to 19, wherein the sample is washed with a detergent solution containing 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol, polyoxyethylene (10) isooctylcyclohexyl ether, polyethylene glycol ether or trimethylnonyl polyethylene glycol. 21. A method according to any one of embodiments 15 to 19, wherein the sample is washed with a detergent solution comprising N-lauroylsarcosine (NLS), potassium laurylsarcosinate, cholate, deoxycholate, sodium dodecyl sulfate (SDS) or polyoxyethylene sorbitan fatty acid esters, optionally Tween 20, Tween 40, Tween 60 or Tween 80. 22. The method of any one of embodiments 15 to 21, wherein the sample is incubated with one or more proteases comprising one or more aminoendopeptidases. 23. The method of any one of embodiments 15 to 22, wherein the sample is incubated with one or more proteases comprising dispase I, dispase II, trypsin, papain, and collagenase. 24. A method according to any one of embodiments 15 to 23, wherein the sample is incubated with one or more nucleases, and the one or more nucleases comprise a non-specific DNA / RNA endonuclease. 25. A method according to any one of embodiments 15 to 24, wherein the sample is incubated with one or more nucleases, wherein the one or more nucleases include universal nuclease, turbo nuclease, alfa-dornase, and a combination of DNase and RNase, optionally including recombinant DNase and RNase. 26. The method according to any one of embodiments 15 to 25, wherein the method comprises performing the following steps in the following order: harvesting biological samples from amphibians; flushing the sample with buffered saline; washing the sample with a detergent solution comprising 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol or NLS; flushing the sample with buffered saline; treating the washed sample with dispase II; Rinse the sample with buffered saline; and treating the washed sample with a universal nuclease to obtain isolated ECM; And optionally, washing the isolated ECM with DPBS. 27. The method of any one of embodiments 15 to 26, wherein the sample is washed with a detergent solution for 6 hours with shaking. 28. A method according to any one of embodiments 15 to 27, wherein the sample is rinsed with DPBS for 5 minutes between washing with the detergent solution and treating with the protease and between treating with the protease and treating with the nuclease. 29. The method of any one of embodiments 15 to 28, wherein the amphibian comprises a froglet, a tadpole, an anuran, or a juvenile anapsid in the larval stage. 30. The method of any one of embodiments 15 to 29, wherein the biological sample comprises ECM tissue from a neotenic anuran. 31. A method according to any one of embodiments 15 to 30, wherein the biological sample comprises ECM of connective tissue, adipose tissue, bone, plasma, skin, cartilage, tendon, dura mater, or fascia. 32. The method of any one of embodiments 15 to 32, wherein the isolated ECM is further micronized. 33. The method of embodiment 32, wherein the isolated ECM can be micronized to a particle size of about 1 to 1000 microns, 1 to 900 microns, 1 to 800 microns, 1 to 700 microns, 1 to 600 microns, 1 to 500 microns, 1 to 400 microns, 1 to 300 microns, 1 to 200 microns, 100 to 300 microns, 100 to 250 microns, 100 to 200 microns, 100 to 150 microns, or 100 to 125 microns. 34. An isolated ECM obtained by the method according to any one of embodiments 15 to 33. 35. A composition comprising the isolated ECM according to embodiment 34 and a carrier. 36. The composition of embodiment 35, wherein the composition is a pharmaceutical composition or a cosmetic composition, and optionally, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and wherein the cosmetic composition comprises a cosmetically acceptable carrier. 37. A composition according to embodiment 35 or 36, wherein the composition further comprises one or more agents, and optionally, wherein the one or more agents are xenogeneic to the isolated ECM. 38. A composition according to any one of embodiments 35 to 37, wherein the composition further comprises one or more pharmaceutical agents, which are peptides, proteins, drugs, nutrients, retinoids, emollients, steroids, carbohydrates, glycoproteins, polymers or combinations thereof. 39. The composition of any one of embodiments 35 to 38, further comprising one or more growth factors, cytokines, chemokines, or a combination thereof. 40. The composition of any one of embodiments 35 to 39, wherein the composition further comprises one or more polymers, and optionally wherein the one or more polymers are synthetic or natural polymers or copolymers. 41. A method of treating and / or preventing a skin disorder, wherein the method comprises administering to a subject in need thereof an isolated ECM according to any one of embodiments 1 to 8 or 34, or a composition according to any one of embodiments 9 to 14 or 35 to 40. 42. The method of embodiment 41, wherein the skin conditions include fine lines and / or wrinkles, aging, redness, abrasions, burns, cuts, infections, shaving rash, scars, uneven skin tone, pain, stretch marks, increasing skin elasticity and / or firmness, improving skin hydration, inflammation, and hyperpigmentation. 43. The method of embodiment 41 or 42, wherein the preventing a skin disorder comprises protecting the skin from damage including ultraviolet light and / or environmental pollution. 44. The method of any one of embodiments 41 to 43, wherein treating and / or preventing a skin condition comprises a skin condition following a dermatological or cosmetic procedure, optionally comprising dermabrasion, microdermabrasion, or exfoliative resurfacing. 45. The method of any one of embodiments 41 to 44, wherein treating and / or preventing a skin disorder comprises using the isolated ECM to improve the appearance of the subject's skin. 46. A preparation comprising the isolated ECM of any one of embodiments 1 to 8 or 34 or the composition of embodiments 9 to 14 or 35 to 40. 47. The formulation of embodiment 46, wherein the formulation is in the form of a powder, solution, paste, liquid, extract, cream, lotion, serum, dispersion, emulsion or ointment. 48. The formulation of embodiment 46 or 47, wherein the formulation comprises 0.001% to 5.0% w / v of isolated ECM. Example
[0098] Example 1. Harvesting skin samples from axolotls
[0099] Auricularia skin sample was obtained or harvested from a neotenic anuran. A 5 x 5 centimeter (cm) full-thickness skin explant sample was surgically excised from a neotenic anuran. The sample was cleaned and prepared for decellularization.
[0100] Example 2. Decellularization of Harvested Axolotl Skin Samples
[0101] Fresh axolotl samples were imaged prior to processing to record appearance. All samples were weighed before and after each step to record weight loss due to decellularization (Table 1).
[0102] washing Three 5×5 cm samples were briefly rinsed with Dulbecco's phosphate buffered saline (DPBS) at room temperature for 5 minutes (min), then washed with Triton X-100 Reduced or NLS at 37°C for 6 hours, followed by a brief rinse with DPBS at room temperature for 5 minutes, and then incubated with one or more proteases. Washing with detergent solution was performed with shaking at 100 RPM.
[0103] Triton X-100 Reduced Wash (Samples T1 and T2): After rinsing with PBS, each 5×5 cm sample was washed twice with 20 ml 0.5% v / v Triton X-100 Reduced (containing 0.02% w / v sodium azide) at 37°C with shaking at 100 RPM for 6 hours each time.
[0104] NLS wash (Sample NLS): After rinsing with PBS, each 5 x 5 sample was washed twice with 25 ml 1.0% NLS (containing 0.02% sodium azide) at 37°C for 6 hours each.
[0105] Protease treatment Each sample was incubated with 2 units / ml of Dispase II (2 units of Dispase II per ml of high glucose DPBS) for 90 minutes at 37°C. Each protease treated sample was briefly rinsed with DPBS for 5 minutes at room temperature.
[0106] Nuclease treatment : After rinsing with DPBS, the protease-treated samples were treated with 40 units / ml of universal nuclease (40 units of universal nuclease per ml of DPBS) for 6 hours at 37° C. Subsequently, the samples were briefly rinsed with DPBS for 5 minutes at room temperature and washed with DPBS for 24 hours at 37° C.
[0107] Example 3. Analysis of isolated ECM
[0108] Hematoxylin and eosin (H&E) staining After decellularization was completed, two (2) 8 mm punch biopsy samples were taken from each of the three samples, one from the upper left corner and one from the center of each 5×5 sample, to compare the success rate of the decellularization process based on anatomical region.
[0109] H&E slides were processed and imaged by light microscopy ( Figures 1A-1F ). The degree of decellularization was evaluated by visual inspection to be more than 80%.
[0110] DN A Quantification. To quantify DNA in the isolated ECM after the decellularization process, 4 mm punch biopsy samples were excised from two different locations of each of the three samples (lower left corner and center of each 5×5 sample). After excision, the samples were immediately transferred to Eppendorf tubes and frozen at -20°C until ready for DNA extraction and quantification. DNA was extracted and purified using the DNEasy Blood & Tissue Kit. The samples were processed according to the protocol included in the kit and subsequently quantified using the NanoDropOne instrument.
[0111] Figure 2A and2B The results shown in the figure indicate that DNA was correctly removed by benzonase treatment. Figure 2A In the figure, samples T1 (T1_C), T2 (T2_C), and NLS (NLS_C) collected from the center of the tissue (C) produced DNA concentrations (ng DNA per microliter of DNA extract) of 4.44 ng / μl ± 0.9, 3.96 ng / μl ± 0.83, and 3.27 ng / μl ± 0.52, respectively. Samples T1_BLC, T2_BLC, and NLS_BLC collected from the lower left corner (BLC) of T1, NLS, and T2 produced DNA concentrations of 7.44 ng / μl ± 3.88, 5.07 ng / μl ± 0.61, and 4.3 ng / μl ± 0.48, respectively. Figure 2B DNA concentrations converted to percentages are shown.
[0112] DNA gel electrophoresis DNA quantification was performed by gel electrophoresis and the Figure 3A and 3B As shown. Samples were prepared with Purple 6X gel loading dye (New England BioLabs, B7024S) at a ratio of 5:1 (DNA: dye). A DNA ladder (GeneRuler Express DNA Ladder Ref#SM1553) was used as a reference. For samples and DNA ladder, a total volume of 12 μL (10 μL DNA sample + 2 μL Purple dye) was used per well. The samples were electrophoresed using an agarose gel (1%) with GelRed Nucleic AcidStain (MilliporeSigma SCT123) at 100 volts for 45 minutes. Subsequently, the gel was removed and imaged using an Azure Biosystems c150 gel imaging device. As shown Figure 3A and 3B As shown, faint DNA bands were observed in the tested samples, indicating that the universal nuclease treatment was effective.
[0113] Example 4. Micronization of isolated ECM
[0114] Cryogenic grinding. T1 and NLS samples were micronized to obtain particles by cryogenic grinding. In a Spex 6870 freezer / grinder, samples were cryogenically ground under the following conditions. First, the samples were quickly frozen in liquid nitrogen without direct exposure. Subsequently, 3 ml of water (Thermo-Scientific, Water, nuclease-free Ref#R0582) without RNA / DNA was added to the cryogenic grinding chamber containing the sample at 1 ml each time. Immediately thereafter, the grinding bullet was placed in a cryogenic grinding device and a total of 6 cycles were run with 5 minutes of precooling, 1 minute of cryogenic grinding, 2 minutes of cooling, and 6 collisions per second. A small amount of slurry samples was retained for visual inspection under an optical microscope. In addition, 15 randomly selected micronized tissue samples were measured by ImageJ and tabulated to assess particle length (fibrous structure) and area (plaque). The fiber length of the TritonX-100 treated sample was 28.36 μm ± 13.19, compared to 30.05 μm ± 34.70 ( Figure 4A The average area of micronized T1 and NLS samples was 494.06 μm 2 ±293.2 and 631.5 μm 2 ±550.91. In addition, the fiber size distribution of the Triton X-100 treated sample was more uniform than that of the NLS treated sample. The results demonstrated that the cryogenic grinding process and settings can effectively micronize the axolotl decellularized tissue to less than 100 μm in length.
[0115] The T2 sample was not micronized but was vacuum dehydrated at 15°C and 360 Torr.
[0116] Freeze-drying . After cryogenic grinding, T1 and NLS samples were immediately transferred to 50 ml conical tubes for lyophilization. The lyophilization process was as follows. The samples were frozen at -45 °C for 5 minutes at 360 Torr. Subsequently, the samples underwent a first drying stage, including freezing at -40 °C for 120 minutes at 100 mTorr, then freezing at -25 °C for 300 minutes at 50 mTorr, and freezing at -25 °C for 720 minutes at 250 mTorr. Finally, the samples underwent a second drying stage, including cooling at +5 °C for 120 minutes at 300 mTorr.
[0117] The above subject matter is provided by way of illustration only and should not be considered as limiting. Various modifications and changes may be made to the subject matter described herein without following the example embodiments and applications shown and described, and without departing from the true spirit and scope of the present disclosure, which is set forth in the following claims.
[0118] Example 5. Treatment of Subjects
[0119] Example 5.1. Topical serum for treating cuts
[0120] A topical serum formulation containing 0.001% to 5.0% weight / volume of the isolated ECM and one or more carriers was prepared. The topical serum was applied to the cut site of the subjects twice daily in the morning and evening. After 8 weeks, the appearance of skin quality was observed.
[0121] Example 5.2. Topical treatment of skin abrasions
[0122] A formulation comprising 0.001% to 5.0% weight / volume of the isolated ECM and optionally one or more other carriers in a petrolatum base is prepared. The formulation is placed in a non-stick bandage. The bandage is applied to the abrasion site of the subject. The bandage is changed daily and the abrasion site is observed to determine the number of days required for skin re-epithelialization.
[0123] For comparison, subjects' abrasions were treated with petrolatum alone. The abrasion sites were observed to determine the number of days required for skin re-epithelialization.
[0124] Example 5.3. Local treatment after ablative laser resurfacing
[0125] A formulation comprising 0.001% to 5.0% weight / volume of isolated ECM and one or more carriers or excipients is prepared and applied daily to the skin of a subject after undergoing ablative laser resurfacing surgery. The skin is observed daily for reduced inflammation and shortened healing time.
[0126] Example 5.4. Topical treatment for burns
[0127] A formulation comprising 0.001% to 5.0% weight / volume of the isolated ECM and optionally one or more other carriers in a petrolatum base is prepared. A subject with a body burn is treated with the formulation. The formulation is placed on a dressing and applied to the subject's burn site. The burn wound is checked daily and the dressing is changed daily or every 48 hours.
[0128] All publications, patents and patent applications cited in this specification are incorporated herein by reference in their entirety, just as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. Although the foregoing has been described according to various embodiments, it will be appreciated by those skilled in the art that various modifications, substitutions, omissions and changes may be made without departing from the spirit thereof. References U.S. Patent 10,617,790.
Claims
1. An isolated amphibian ECM, wherein: The ECM is decellularized, and the ECM comprises: Intact native ECM structure; only 1% to 10% of the total DNA present in the corresponding native ECM samples; Residual DNA fragments less than 300 bases (bp); and / or More than 70% of the ECM was decellularized.
2. The ECM of claim 1, wherein: The ECM comprises 2% to 10% of the total amount of DNA present in the corresponding native ECM sample.
3. The ECM of claim 1, wherein: The ECM contains residual DNA fragments with a length of 50 bp to 300 bp.
4. The ECM of claim 3, wherein: The ECM contains residual DNA fragments less than 250 bp in length.
5. The ECM of claim 1, wherein: The ECM has had 80% to 90% of its cells removed.
6. The ECM of claim 1, wherein: The ECM is in the form of a dry powder, paste, solution, extract, cream, lotion, dispersion or emulsion.
7. The ECM of claim 1, wherein: The ECM is obtained from a juvenile amphibian, optionally comprising a froglet, a tadpole, anuran, or a larval stage juvenile anapsid.
8. The ECM of claim 1, wherein: The ECM is obtained from neotenic anurans.
9. A composition, wherein The composition comprises a carrier and an ECM according to any one of claims 1 to 8.
10. The composition according to claim 9, wherein The composition is a pharmaceutical composition or a cosmetic composition, and optionally, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and wherein the cosmetic composition comprises a cosmetically acceptable carrier.
11. The composition according to claim 10, wherein The composition further comprises one or more agents, and optionally, wherein the one or more agents are xenogeneic to the isolated ECM.
12. The composition according to claim 10, wherein The composition further comprises one or more pharmaceutical agents comprising a peptide, a protein, a drug, a nutrient, a retinoid, an emollient, a steroid, a carbohydrate, a glycoprotein, a polymer, or a combination thereof.
13. The composition according to claim 10, wherein The composition further comprises one or more growth factors, cytokines, chemokines, or a combination thereof.
14. The composition according to claim 9, wherein The composition further comprises one or more polymers, and optionally, wherein the one or more polymers are synthetic or natural polymers or copolymers.
15. A method for decellularizing amphibian ECM, wherein: The method comprises harvesting a biological sample from an amphibian, washing the sample with a detergent solution, and treating the sample with one or more proteases and one or more nucleases to obtain isolated ECM.
16. The method according to claim 15, wherein: The method comprises: harvesting a biological sample from an amphibian, rinsing the sample with a solution, washing the sample with a detergent solution, treating the sample with a protease, rinsing the sample after the protease treatment, and treating the rinsed protease-treated sample with a nuclease to obtain an isolated ECM, and optionally, further washing the isolated ECM.
17. The method according to claim 16, wherein: The method comprises: washing the sample with water or a buffer solution, optionally with phosphate buffered saline (PBS) or Dulbecco's phosphate buffered saline (DPBS).
18. The method according to claim 16, wherein: The sample is washed with a detergent solution comprising one or more surfactants, and optionally wherein the one or more surfactants comprise one or more nonionic surfactants or anionic surfactants.
19. The method according to claim 16, wherein: The sample is washed with a detergent solution containing 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol, polyoxyethylene (10) isooctylcyclohexyl ether, polyethylene glycol ether, or trimethylnonyl polyethylene glycol.
20. The method according to claim 16, wherein: The sample is washed with a detergent solution containing N-lauroylsarcosine (NLS), potassium laurylsarcosinate, cholate, deoxycholate, sodium dodecyl sulfate (SDS) or polyoxyethylene sorbitan fatty acid esters, optionally Tween 20, Tween 40, Tween 60 or Tween 80.
21. The method according to claim 16, wherein: The sample is incubated with one or more proteases comprising one or more aminoendopeptidases, and optionally wherein the one or more proteases comprise one or more of dispase I, dispase II, trypsin, papain and collagenase.
22. The method according to claim 16, wherein: The sample is incubated with one or more nucleases, the one or more nucleases comprising a non-specific DNA / RNA endonuclease, and optionally, wherein the one or more nucleases comprise a universal nuclease, a turbo nuclease, a dornase alfa, and a combination of a DNase and a RNase, optionally comprising a recombinant DNase and a RNase.
23. The method according to claim 16, wherein: The method comprises the following steps in the following order: harvesting biological samples from amphibians; flushing the sample with buffered saline; washing the sample with a detergent solution comprising 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol or NLS; flushing the sample with buffered saline; treating the washed sample with dispase II; flushing the sample with buffered saline; as well as treating the washed sample with a universal nuclease to obtain isolated ECM; And optionally, washing the isolated ECM with DPBS.
24. The method according to claim 23, wherein: The samples were washed with detergent solution for 6 hours with shaking.
25. The method according to claim 23, wherein: The samples were rinsed with DPBS for 5 minutes between washing with detergent solution and treatment with protease and between treatment with protease and treatment with nuclease.
26. The method of claim 16, wherein: The amphibians include froglets, tadpoles, uropods or juvenile anapsids in the larval stage.
27. The method of claim 16, wherein: The biological sample comprises ECM tissue from a neotenic anuran.
28. The method of claim 16, wherein: The biological sample includes ECM of connective tissue, adipose tissue, bone, plasma, skin, cartilage, tendon, dura mater or fascia.
29. The method of claim 16, wherein: The isolated ECM was further micronized.
30. The method of claim 29, wherein: The isolated ECM can be micronized to a particle size of about 1 to 1000 microns, 1 to 900 microns, 1 to 800 microns, 1 to 700 microns, 1 to 600 microns, 1 to 500 microns, 1 to 400 microns, 1 to 300 microns, 1 to 200 microns, 100 to 300 microns, 100 to 250 microns, 100 to 200 microns, 100 to 150 microns, or 100 to 125 microns.
31. An isolated ECM obtained by the method according to any one of claims 15 to 30.
32. The composition according to claim 31, wherein The composition is a pharmaceutical composition or a cosmetic composition, and optionally, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and wherein the cosmetic composition comprises a cosmetically acceptable carrier.
33. A method for treating and / or preventing skin disorders, wherein: The method comprises administering to a subject in need thereof an isolated ECM according to any one of claims 1 to 8 or 31 or a composition according to any one of claims 10 to 14 or 32.
34. The method of claim 33, wherein: Such skin conditions include fine lines and / or wrinkles, aging, redness, abrasions, burns, cuts, infections, shaving rash, scars, uneven skin tone, pain, stretch marks, increasing skin elasticity and / or firmness, improving skin hydration, inflammation, and hyperpigmentation.
35. The method of claim 33, wherein: Such prevention of skin disorders includes protecting the skin from damaging agents including ultraviolet light and / or environmental pollution.
Citation Information
Cited By
Spirit skin extract as well as preparation method and application thereof
CN119837816A
A skin extract of axolotl, its preparation method and application
CN119837816B
